Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics

KKRX:323990
3,685.00
KRW
-120.00
(-3.15%)
-644.75EPS
118.42BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.7
82.76
305.21
281.41
Basic EPS, GAAP
-107.75
-441.14
-237.35
-337.56
-524
-463
-577
-644.75
Free Cash Flow per Basic Share
-386.05
-369.27
-343.33
-313.32
-490.72
-643.47
-752.88
-786.56
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
456.07
3,472.23
1,488.89
1,154.63
3,635.75
3,142.51
2,637.94
2,298.92
Tangible Book Value per Share
452.18
3,465.34
1,481.58
1,143.27
3,626.75
2,933.43
2,333.23
1,997.03
Basic Weighted Avg Shares
12
9
20
20
20
23
23
23
Sales/Revenue/Turnover
- -
- -
- -
- -
14
1,899
7,056
6,511
Operating Margin (%)
- -
- -
- -
- -
-83,851.26
-791.66
-219.51
-256.88
Depreciation Expense
185
185
257
311
400
1,466
2,181
2,389
Net Income, GAAP
-1,254
-3,984
-4,763
-6,825
-10,274
-10,624
-13,340
-14,918
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-74,865.84
-559.45
-189.05
-229.11
Working Capital
7,892
18,592
27,805
20,591
50,303
36,285
26,486
16,006
LT Debt
301
153
37
59
144
1,403
1,093
613
Total Equity
9,071
34,667
30,080
23,327
83,493
71,994
61,131
53,275
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-18.22
-14.71
-25.56
-19.24
-13.66
-20.04
-24.64

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
896
699
942
LT Borrowings
- -
- -
- -
LT Finance Leases
1,093
1,093
613
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
231,507
176,817
118,419

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
30,004
25,122
19,513
Cash, Cash Equivalents & STI
25,194
19,738
15,208
Accounts Receivable, Net
2,814
2,714
2,738
Inventories
324
399
355
Total Current Liabilities
3,518
4,087
3,507
Payables & Accruals
- -
- -
- -
ST Debt
896
699
942
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38.68%
-15.09%
Free Cash Flow
- -
44.35%
17.89%
Net Income, GAAP
- -
28.47%
25.57%
Sales/Revenue/Turnover
- -
- -
271.59%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
27
29
483
- -
1,899
2025
1,719
1,986
1,654
1,696
7,056
2026
1,536
1,625
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-107
-106
-104.89
- -
-463
2025
-121
-165
-116.25
-182.07
-577
2026
-171.27
-175
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jae-Jung Lee
Full Time Employees
91
Sector
Health technology
Industry
Biotechnology
Address
12-55, Sandan-gil Hwasun-gun SJ South Korea 58141
IPO Date
Sep 22, 2020
Business
Vaxcell-Bio Therapeutics Co., Ltd. is a South Korean biotechnology company specializing in the research, development, manufacturing, and commercialization of cancer immunotherapy products. Its core products include cell-based immunotherapies such as the Vax-NK natural killer cell platform; the Vax-DC dendritic cell platform; and next-generation CAR therapies including the Vax-CAR series, which target solid tumors and hematological cancers. The company also produces cytokine-based immunotherapy products like Bosuleukin-15 specifically for canine cancer treatment. Founded in 2010 and headquartered in Hwasun-eup, South Korea, Vaxcell-Bio operates primarily within South Korea while also targeting overseas markets. Recent major developments include the completion of the acquisition of ALBIOTEK Co., Ltd. in early 2025, strategic alliances for advancing CAR-NK and CAR-T cell therapies aimed at solid tumors, and significant progress in clinical trials for its Vax-NK therapies showing superior efficacy in liver and pancreatic cancers. The company has also secured patents for novel dual-target CAR-T therapies and received government grants to develop next-generation CAR-NK and CAR-MIL cell therapies. Additionally, Vaxcell-Bio is expanding its capabilities in cell therapy contract development and manufacturing organizations (CDMO) and partnering with institutions such as Seoul National University for innovative treatments including macular degeneration. These actions emphasize Vaxcell-Bio’s focus on advancing cellular immuno-oncology and expanding its product offerings in cancer immunotherapy markets.